UNSPSC 51283504: Nafcillin

This classification denotes a beta-lactam antibiotic with the molecular formula C21H22N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4CNZ27M7RV, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-ethoxy-1-naphthamido)-3,3-dimethyl-7-oxo- but generally known as nafcillin, which bears US NIH Compound Identifier 8982. European Medicines Agency schedules Nafcillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09118MIG.

UNSPSC 51283504 Nafcillin is a Commodity code for a specific antibiotic pharmaceutical product, but the recent state and local opportunities posted under this code do not reflect nafcillin procurement. Instead, the tagged solicitations cover unrelated pharmaceutical categories — antibiotic tablets (doxycycline and ciprofloxacin) and emergency response supplies (naloxone and drug deactivation systems) — indicating a mismatch between the code assignment and the work actually being bought. State and local purchasing offices appear to use this code inconsistently or as a catchall for pharmaceutical warehouse and emergency-supply contracts. The issuing bodies include state health departments and county government procurement offices, both of which pursue pharmaceutical supply through cooperative purchasing vehicles and competitive bidding.

The geographic spread of recent activity includes Illinois and Florida. The Illinois Department of Public Health awarded a $2.999 million three-year pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for doxycycline and ciprofloxacin tablets on an IFB basis. Seminole County, Florida solicited naloxone and drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually) through an IFB posted June 30, 2026, with a response deadline of July 26, 2026, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford. The code shows limited recent activity aligned to its nominal scope; firms pursuing pharmaceutical procurement should verify code assignment against the actual product line before committing resources.